Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca & Sputnik V COVID-19 Vaccine Combo To Enter Trial

Russians Claim The Lead In Heterologous Coronavirus Vaccination

Executive Summary

There is growing in interest in boosting the first dose of a COVID-19 vaccine by administering a different vaccine as the second dose.

You may also be interested in...



Coronavirus Notebook: EU Filing For Russian Vaccine, UK Links With CureVac Against Virus Variants

There is some good news from UK and EU vaccine safety reviews, the WHO reports on COVAX vaccine distribution to less well off countries, and the European Commission and Pfizer agree on the supply of 300 million more vaccine doses.

Coronavirus Notebook: UK ‘Com-Cov’ Trial To Test Alternating Vaccines, EMA Pilots Assessment Sharing Scheme

The director of the World Health Organization and the NGO, Médecins Sans Frontières, have both called for monopolies on COVID-19 products to be waived during the pandemic. And confounding critics, new analysis in The Lancet shows the Oxford/AZ vaccine works best with a 12-week dosing interval.

Coronavirus Notebook: Russia Has “No Immediate Plans” To File Sputnik V In UK Or US; EU Pressured On Vaccine Contract Disclosure

The European Commission insists companies will deliver vaccines on schedule, the Ombudsman starts up a new inquiry into access to vaccine deal documents, and Europe’s disease control center kicks off its “COVID-19 vaccine tracker.”

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1131867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel